Hyoscine butylbromide in pain reduction associated with ultrasound-guided manual vacuum aspiration: a randomized placebo-controlled trial
•Ultrasound-guided manual vacuum aspiration causes painful uterine contraction.•Abdominal pain during USG-MVA is insignificantly reduced by hyoscine butylbromide.•Alternative anti-spasmodics or higher dosage should be investigated. What is the effect of adding an anti-spasmodic drug to an existing u...
Gespeichert in:
| Veröffentlicht in: | Reproductive biomedicine online 2022-02, Vol.44 (2), p.295-303 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 303 |
|---|---|
| container_issue | 2 |
| container_start_page | 295 |
| container_title | Reproductive biomedicine online |
| container_volume | 44 |
| creator | Chung, Jacqueline Pui Wah Law, Tracy Sze Man Mak, Jennifer Sze Man Liu, Rebecca Chui Yiu Sahota, Daljit Singh Li, Tin Chiu |
| description | •Ultrasound-guided manual vacuum aspiration causes painful uterine contraction.•Abdominal pain during USG-MVA is insignificantly reduced by hyoscine butylbromide.•Alternative anti-spasmodics or higher dosage should be investigated.
What is the effect of adding an anti-spasmodic drug to an existing ultrasound-guided manual vacuum aspiration (USG-MVA) protocol to alleviate immediate post-procedure abdominal cramping pain in women treated for early pregnancy loss?
Double-blind, placebo-controlled, randomized controlled trial conducted between February 2018 and January 2020. Participants were assigned to receive a 1-ml intravenous injection containing 20-mg hyoscine butylbromide (HBB) (n=55) or saline (n =56) as a control immediately before USG-MVA. Primary outcome was reduced abdominal pain after adding a 20-mg dose of HBB to the current pain control regimen. Secondary outcomes were vaginal pain, complications and side-effects, women's pre- and post-procedure psychological state, physiological stress (saliva alpha-amylase) and procedure pain control satisfaction. Two-way mixed ANOVA was used to evaluate the main effects and interactions.
VAS abdominal pain scores in the HBB group were 16% lower immediately after and 21% lower 2 h after surgery (not statistically significant). Two-way ANOVA indicated that time (F[1108] = 83.41, P < 0.001) was the only significant main effect for reduced abdominal pain after the procedure and vaginal pain score (F[1108] = 180.1, P < 0.0001) but not drug received. No adverse events were reported. No significant difference was found for psychological state, physiological stress and procedure pain control satisfaction between the two groups.
Anti-spasmodic drugs can help to reduce abdominal cramping pain associated with USG-MVA; HBB produced an insignificant decrease in abdominal pain score. Further studies with longer acting or larger doses of anti-spasmodic drugs are warranted. |
| doi_str_mv | 10.1016/j.rbmo.2021.10.011 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2614240009</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1472648321005253</els_id><sourcerecordid>2614240009</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-d805b1a028fd818c58b63b2f8fbfbbcd959ec1af5795b0f7e2662e13abe4dbbe3</originalsourceid><addsrcrecordid>eNp9kc1uFDEQhEcRiITAC3BAPnKZxfb8rAdxQVFCkCJxgbPVtnuCVx578E_Q8ga8NR5tyJFLu1X6qqR2Nc0bRneMsvH9YRfVEnacclaFHWXsrLlg_Z63Yz-xZ0-76M6blykdKGWCiu5Fc971Uz8Nnbho_tweQ9LWI1ElH52KYbEGifVkhToimqKzDZ5ASkFbyGjIL5t_kOJyhBSKN-19qRZDFvAFHHkAXcpS-dVG2KwfCJAI3tTk3xVbHWhUodXB5xicq1KOFtyr5vkMLuHrx_ey-X5z_e3qtr37-vnL1ae7VnfDmFsj6KAYUC5mI5jQg1Bjp_gsZjUrpc00TKgZzMN-GhSd98jHkSPrQGFvlMLusnl3yl1j-FkwZbnYpNE58BhKknxkPe8ppVNF-QnVMaQUcZZrtAvEo2RUbhXIg9wqkFsFm1YrqKa3j_lFLWieLP_-vAIfTwDWKx8sRlkLQK_R2Ig6SxPs__L_Au4snNE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2614240009</pqid></control><display><type>article</type><title>Hyoscine butylbromide in pain reduction associated with ultrasound-guided manual vacuum aspiration: a randomized placebo-controlled trial</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Chung, Jacqueline Pui Wah ; Law, Tracy Sze Man ; Mak, Jennifer Sze Man ; Liu, Rebecca Chui Yiu ; Sahota, Daljit Singh ; Li, Tin Chiu</creator><creatorcontrib>Chung, Jacqueline Pui Wah ; Law, Tracy Sze Man ; Mak, Jennifer Sze Man ; Liu, Rebecca Chui Yiu ; Sahota, Daljit Singh ; Li, Tin Chiu</creatorcontrib><description>•Ultrasound-guided manual vacuum aspiration causes painful uterine contraction.•Abdominal pain during USG-MVA is insignificantly reduced by hyoscine butylbromide.•Alternative anti-spasmodics or higher dosage should be investigated.
What is the effect of adding an anti-spasmodic drug to an existing ultrasound-guided manual vacuum aspiration (USG-MVA) protocol to alleviate immediate post-procedure abdominal cramping pain in women treated for early pregnancy loss?
Double-blind, placebo-controlled, randomized controlled trial conducted between February 2018 and January 2020. Participants were assigned to receive a 1-ml intravenous injection containing 20-mg hyoscine butylbromide (HBB) (n=55) or saline (n =56) as a control immediately before USG-MVA. Primary outcome was reduced abdominal pain after adding a 20-mg dose of HBB to the current pain control regimen. Secondary outcomes were vaginal pain, complications and side-effects, women's pre- and post-procedure psychological state, physiological stress (saliva alpha-amylase) and procedure pain control satisfaction. Two-way mixed ANOVA was used to evaluate the main effects and interactions.
VAS abdominal pain scores in the HBB group were 16% lower immediately after and 21% lower 2 h after surgery (not statistically significant). Two-way ANOVA indicated that time (F[1108] = 83.41, P < 0.001) was the only significant main effect for reduced abdominal pain after the procedure and vaginal pain score (F[1108] = 180.1, P < 0.0001) but not drug received. No adverse events were reported. No significant difference was found for psychological state, physiological stress and procedure pain control satisfaction between the two groups.
Anti-spasmodic drugs can help to reduce abdominal cramping pain associated with USG-MVA; HBB produced an insignificant decrease in abdominal pain score. Further studies with longer acting or larger doses of anti-spasmodic drugs are warranted.</description><identifier>ISSN: 1472-6483</identifier><identifier>EISSN: 1472-6491</identifier><identifier>DOI: 10.1016/j.rbmo.2021.10.011</identifier><identifier>PMID: 34949538</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Abdominal Pain - chemically induced ; Abdominal Pain - drug therapy ; Buscopan ; Butylscopolammonium Bromide - adverse effects ; Butylscopolammonium Bromide - therapeutic use ; Double-Blind Method ; Early pregnancy loss ; Female ; Humans ; Hydrocarbons, Brominated ; Hyoscine butylbromide ; Manual vacuum aspiration ; Pain control ; Pregnancy ; Scopolamine - therapeutic use ; Ultrasonography, Interventional ; Ultrasound-guided ; Vacuum Curettage</subject><ispartof>Reproductive biomedicine online, 2022-02, Vol.44 (2), p.295-303</ispartof><rights>2021 Reproductive Healthcare Ltd.</rights><rights>Copyright © 2021 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-d805b1a028fd818c58b63b2f8fbfbbcd959ec1af5795b0f7e2662e13abe4dbbe3</citedby><cites>FETCH-LOGICAL-c356t-d805b1a028fd818c58b63b2f8fbfbbcd959ec1af5795b0f7e2662e13abe4dbbe3</cites><orcidid>0000-0002-9742-578X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.rbmo.2021.10.011$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34949538$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chung, Jacqueline Pui Wah</creatorcontrib><creatorcontrib>Law, Tracy Sze Man</creatorcontrib><creatorcontrib>Mak, Jennifer Sze Man</creatorcontrib><creatorcontrib>Liu, Rebecca Chui Yiu</creatorcontrib><creatorcontrib>Sahota, Daljit Singh</creatorcontrib><creatorcontrib>Li, Tin Chiu</creatorcontrib><title>Hyoscine butylbromide in pain reduction associated with ultrasound-guided manual vacuum aspiration: a randomized placebo-controlled trial</title><title>Reproductive biomedicine online</title><addtitle>Reprod Biomed Online</addtitle><description>•Ultrasound-guided manual vacuum aspiration causes painful uterine contraction.•Abdominal pain during USG-MVA is insignificantly reduced by hyoscine butylbromide.•Alternative anti-spasmodics or higher dosage should be investigated.
What is the effect of adding an anti-spasmodic drug to an existing ultrasound-guided manual vacuum aspiration (USG-MVA) protocol to alleviate immediate post-procedure abdominal cramping pain in women treated for early pregnancy loss?
Double-blind, placebo-controlled, randomized controlled trial conducted between February 2018 and January 2020. Participants were assigned to receive a 1-ml intravenous injection containing 20-mg hyoscine butylbromide (HBB) (n=55) or saline (n =56) as a control immediately before USG-MVA. Primary outcome was reduced abdominal pain after adding a 20-mg dose of HBB to the current pain control regimen. Secondary outcomes were vaginal pain, complications and side-effects, women's pre- and post-procedure psychological state, physiological stress (saliva alpha-amylase) and procedure pain control satisfaction. Two-way mixed ANOVA was used to evaluate the main effects and interactions.
VAS abdominal pain scores in the HBB group were 16% lower immediately after and 21% lower 2 h after surgery (not statistically significant). Two-way ANOVA indicated that time (F[1108] = 83.41, P < 0.001) was the only significant main effect for reduced abdominal pain after the procedure and vaginal pain score (F[1108] = 180.1, P < 0.0001) but not drug received. No adverse events were reported. No significant difference was found for psychological state, physiological stress and procedure pain control satisfaction between the two groups.
Anti-spasmodic drugs can help to reduce abdominal cramping pain associated with USG-MVA; HBB produced an insignificant decrease in abdominal pain score. Further studies with longer acting or larger doses of anti-spasmodic drugs are warranted.</description><subject>Abdominal Pain - chemically induced</subject><subject>Abdominal Pain - drug therapy</subject><subject>Buscopan</subject><subject>Butylscopolammonium Bromide - adverse effects</subject><subject>Butylscopolammonium Bromide - therapeutic use</subject><subject>Double-Blind Method</subject><subject>Early pregnancy loss</subject><subject>Female</subject><subject>Humans</subject><subject>Hydrocarbons, Brominated</subject><subject>Hyoscine butylbromide</subject><subject>Manual vacuum aspiration</subject><subject>Pain control</subject><subject>Pregnancy</subject><subject>Scopolamine - therapeutic use</subject><subject>Ultrasonography, Interventional</subject><subject>Ultrasound-guided</subject><subject>Vacuum Curettage</subject><issn>1472-6483</issn><issn>1472-6491</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1uFDEQhEcRiITAC3BAPnKZxfb8rAdxQVFCkCJxgbPVtnuCVx578E_Q8ga8NR5tyJFLu1X6qqR2Nc0bRneMsvH9YRfVEnacclaFHWXsrLlg_Z63Yz-xZ0-76M6blykdKGWCiu5Fc971Uz8Nnbho_tweQ9LWI1ElH52KYbEGifVkhToimqKzDZ5ASkFbyGjIL5t_kOJyhBSKN-19qRZDFvAFHHkAXcpS-dVG2KwfCJAI3tTk3xVbHWhUodXB5xicq1KOFtyr5vkMLuHrx_ey-X5z_e3qtr37-vnL1ae7VnfDmFsj6KAYUC5mI5jQg1Bjp_gsZjUrpc00TKgZzMN-GhSd98jHkSPrQGFvlMLusnl3yl1j-FkwZbnYpNE58BhKknxkPe8ppVNF-QnVMaQUcZZrtAvEo2RUbhXIg9wqkFsFm1YrqKa3j_lFLWieLP_-vAIfTwDWKx8sRlkLQK_R2Ig6SxPs__L_Au4snNE</recordid><startdate>202202</startdate><enddate>202202</enddate><creator>Chung, Jacqueline Pui Wah</creator><creator>Law, Tracy Sze Man</creator><creator>Mak, Jennifer Sze Man</creator><creator>Liu, Rebecca Chui Yiu</creator><creator>Sahota, Daljit Singh</creator><creator>Li, Tin Chiu</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9742-578X</orcidid></search><sort><creationdate>202202</creationdate><title>Hyoscine butylbromide in pain reduction associated with ultrasound-guided manual vacuum aspiration: a randomized placebo-controlled trial</title><author>Chung, Jacqueline Pui Wah ; Law, Tracy Sze Man ; Mak, Jennifer Sze Man ; Liu, Rebecca Chui Yiu ; Sahota, Daljit Singh ; Li, Tin Chiu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-d805b1a028fd818c58b63b2f8fbfbbcd959ec1af5795b0f7e2662e13abe4dbbe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Abdominal Pain - chemically induced</topic><topic>Abdominal Pain - drug therapy</topic><topic>Buscopan</topic><topic>Butylscopolammonium Bromide - adverse effects</topic><topic>Butylscopolammonium Bromide - therapeutic use</topic><topic>Double-Blind Method</topic><topic>Early pregnancy loss</topic><topic>Female</topic><topic>Humans</topic><topic>Hydrocarbons, Brominated</topic><topic>Hyoscine butylbromide</topic><topic>Manual vacuum aspiration</topic><topic>Pain control</topic><topic>Pregnancy</topic><topic>Scopolamine - therapeutic use</topic><topic>Ultrasonography, Interventional</topic><topic>Ultrasound-guided</topic><topic>Vacuum Curettage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chung, Jacqueline Pui Wah</creatorcontrib><creatorcontrib>Law, Tracy Sze Man</creatorcontrib><creatorcontrib>Mak, Jennifer Sze Man</creatorcontrib><creatorcontrib>Liu, Rebecca Chui Yiu</creatorcontrib><creatorcontrib>Sahota, Daljit Singh</creatorcontrib><creatorcontrib>Li, Tin Chiu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Reproductive biomedicine online</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chung, Jacqueline Pui Wah</au><au>Law, Tracy Sze Man</au><au>Mak, Jennifer Sze Man</au><au>Liu, Rebecca Chui Yiu</au><au>Sahota, Daljit Singh</au><au>Li, Tin Chiu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hyoscine butylbromide in pain reduction associated with ultrasound-guided manual vacuum aspiration: a randomized placebo-controlled trial</atitle><jtitle>Reproductive biomedicine online</jtitle><addtitle>Reprod Biomed Online</addtitle><date>2022-02</date><risdate>2022</risdate><volume>44</volume><issue>2</issue><spage>295</spage><epage>303</epage><pages>295-303</pages><issn>1472-6483</issn><eissn>1472-6491</eissn><abstract>•Ultrasound-guided manual vacuum aspiration causes painful uterine contraction.•Abdominal pain during USG-MVA is insignificantly reduced by hyoscine butylbromide.•Alternative anti-spasmodics or higher dosage should be investigated.
What is the effect of adding an anti-spasmodic drug to an existing ultrasound-guided manual vacuum aspiration (USG-MVA) protocol to alleviate immediate post-procedure abdominal cramping pain in women treated for early pregnancy loss?
Double-blind, placebo-controlled, randomized controlled trial conducted between February 2018 and January 2020. Participants were assigned to receive a 1-ml intravenous injection containing 20-mg hyoscine butylbromide (HBB) (n=55) or saline (n =56) as a control immediately before USG-MVA. Primary outcome was reduced abdominal pain after adding a 20-mg dose of HBB to the current pain control regimen. Secondary outcomes were vaginal pain, complications and side-effects, women's pre- and post-procedure psychological state, physiological stress (saliva alpha-amylase) and procedure pain control satisfaction. Two-way mixed ANOVA was used to evaluate the main effects and interactions.
VAS abdominal pain scores in the HBB group were 16% lower immediately after and 21% lower 2 h after surgery (not statistically significant). Two-way ANOVA indicated that time (F[1108] = 83.41, P < 0.001) was the only significant main effect for reduced abdominal pain after the procedure and vaginal pain score (F[1108] = 180.1, P < 0.0001) but not drug received. No adverse events were reported. No significant difference was found for psychological state, physiological stress and procedure pain control satisfaction between the two groups.
Anti-spasmodic drugs can help to reduce abdominal cramping pain associated with USG-MVA; HBB produced an insignificant decrease in abdominal pain score. Further studies with longer acting or larger doses of anti-spasmodic drugs are warranted.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>34949538</pmid><doi>10.1016/j.rbmo.2021.10.011</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-9742-578X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1472-6483 |
| ispartof | Reproductive biomedicine online, 2022-02, Vol.44 (2), p.295-303 |
| issn | 1472-6483 1472-6491 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2614240009 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Abdominal Pain - chemically induced Abdominal Pain - drug therapy Buscopan Butylscopolammonium Bromide - adverse effects Butylscopolammonium Bromide - therapeutic use Double-Blind Method Early pregnancy loss Female Humans Hydrocarbons, Brominated Hyoscine butylbromide Manual vacuum aspiration Pain control Pregnancy Scopolamine - therapeutic use Ultrasonography, Interventional Ultrasound-guided Vacuum Curettage |
| title | Hyoscine butylbromide in pain reduction associated with ultrasound-guided manual vacuum aspiration: a randomized placebo-controlled trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T19%3A41%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hyoscine%20butylbromide%20in%20pain%20reduction%20associated%20with%20ultrasound-guided%20manual%20vacuum%20aspiration:%20a%20randomized%20placebo-controlled%20trial&rft.jtitle=Reproductive%20biomedicine%20online&rft.au=Chung,%20Jacqueline%20Pui%20Wah&rft.date=2022-02&rft.volume=44&rft.issue=2&rft.spage=295&rft.epage=303&rft.pages=295-303&rft.issn=1472-6483&rft.eissn=1472-6491&rft_id=info:doi/10.1016/j.rbmo.2021.10.011&rft_dat=%3Cproquest_cross%3E2614240009%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2614240009&rft_id=info:pmid/34949538&rft_els_id=S1472648321005253&rfr_iscdi=true |